{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:15:49Z","timestamp":1791605749770,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The excess thyroid hormone secretion that characterises Graves\u2019 disease (GD) is generated when stimulatory antibodies bind to the thyroid stimulating hormone receptor on the follicular cell of the thyroid gland.<\/jats:p><jats:p>This underlying mechanism cannot easily be abolished and the mainstay of Graves\u2019 disease (GD) management in the young remains thionamide anti-thyroid drug (ATD). Unfortunately, GD will usually recur after a 2 or 3 year course of ATD, even when the stimulatory antibody titres have fallen. The diagnosis of GD therefore usually signals the start of a lengthy period of out-patient assessments and associated venepuncture. Careful, more protracted administration of ATD may increase the likelihood of longer-term remission and reduce the likelihood of the patient developing ATD side-effects. An understanding of how best to use ATD and an awareness of the less well-known consequences of GD and its\u2019 treatment - such as excessive weight-gain and long-term hypothyroidism \u2013 are also of fundamental importance.<\/jats:p><jats:p>Recent clinical studies have shed light on how best to manage the young patient with GD and the associated new information will help to answer some of the questions posed by the young person and their family at diagnosis. This new knowledge is the focus of this article about ATD therapy in the young.<\/jats:p>","DOI":"10.1186\/s13044-021-00109-x","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T08:03:14Z","timestamp":1626854594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["How to use thionamide anti-thyroid drug in the young\u2013 what\u2019s new?"],"prefix":"10.1186","volume":"14","author":[{"given":"Tim","family":"Cheetham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"issue":"3","key":"109_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2265.2009.03717.x","volume":"72","author":"S Williamson","year":"2010","unstructured":"Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clin Endocrinol. 2010;72(3):358\u201363. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03717.x.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"109_CR2","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1210\/jcem.86.2.7242","volume":"86","author":"TH Brix","year":"2001","unstructured":"Brix TH, Kyvik KO, Christensen K, Heged\u00fcs L. Evidence for a major role of heredity in Graves\u2019 disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86(2):930\u20134. https:\/\/doi.org\/10.1210\/jcem.86.2.7242.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"109_CR3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1046\/j.1365-2265.2003.01778.x","volume":"58","author":"B Vaidya","year":"2003","unstructured":"Vaidya B, Oakes EJ, Imrie H, Dickinson AJ, Perros P, Kendall-Taylor P, et al. CTLA4 gene and Graves\u2019 disease: association of Graves\u2019 disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin Endocrinol. 2003;58(6):732\u20135. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01778.x.","journal-title":"Clin Endocrinol"},{"issue":"1\u20132","key":"109_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.mce.2010.01.013","volume":"322","author":"OJ Brand","year":"2010","unstructured":"Brand OJ, Gough SC. Genetics of thyroid autoimmunity and the role of the TSHR. Mol Cell Endocrinol. 2010;322(1\u20132):135\u201343. https:\/\/doi.org\/10.1016\/j.mce.2010.01.013.","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"109_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","volume":"269","author":"MF Prummel","year":"1993","unstructured":"Prummel MF, Wiersinga WM. Smoking and risk of Graves\u2019 disease. JAMA. 1993;269(4):479\u201382. https:\/\/doi.org\/10.1001\/jama.1993.03500040045034.","journal-title":"JAMA."},{"issue":"4","key":"109_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.1365-2265.2001.01252.x","volume":"54","author":"GW Wong","year":"2001","unstructured":"Wong GW, Cheng PS. Increasing incidence of childhood Graves\u2019 disease in Hong Kong: a follow-up study. Clin Endocrinol. 2001;54(4):547\u201350. https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01252.x.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"109_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000430985","volume":"84","author":"R Havgaard Kj\u00e6r","year":"2015","unstructured":"Havgaard Kj\u00e6r R, Smedeg\u00e5rd Andersen M, Hansen D. Increasing incidence of juvenile thyrotoxicosis in Denmark: a Nationwide study, 1998-2012. Horm Res Paediatr. 2015;84(2):102\u20137. https:\/\/doi.org\/10.1159\/000430985.","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"109_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000500265","volume":"91","author":"M Rodanaki","year":"2019","unstructured":"Rodanaki M, Lodefalk M, Forssell K, Arvidsson CG, Forssberg M, Aman J. The incidence of childhood thyrotoxicosis is increasing in both girls and boys in Sweden. Horm Res Paediat. 2019;91(3):195\u2013202. https:\/\/doi.org\/10.1159\/000500265.","journal-title":"Horm Res Paediat"},{"issue":"3","key":"109_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1210\/jcem.85.3.6430","volume":"85","author":"A Allahabadia","year":"2000","unstructured":"Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab. 2000;85(3):1038\u201342. https:\/\/doi.org\/10.1210\/jcem.85.3.6430.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"109_CR10","doi-asserted-by":"publisher","first-page":"e3277","DOI":"10.1210\/clinem\/dgaa347","volume":"105","author":"LC Lane","year":"2020","unstructured":"Lane LC, Ku\u015b A, Bednarczuk T, Bossowski A, Daroszewski J, Jurecka-Lubieniecka B, et al. An Intronic HCP5 variant is associated with age of onset and susceptibility to graves disease in UK and polish cohorts. J Clin Endocrinol Metab. 2020;105(9):e3277\u201384. https:\/\/doi.org\/10.1210\/clinem\/dgaa347.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11\u201312","key":"109_CR11","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1515\/jpem-2013-0050","volume":"26","author":"AP Sohal","year":"2013","unstructured":"Sohal AP, Dasarathi M, Lodh R, Cheetham T, Devlin AM. Speech and language delay in two children: an unusual presentation of hyperthyroidism. J Pediatr Endocrinol Metab. 2013;26(11\u201312):1171\u20134. https:\/\/doi.org\/10.1515\/jpem-2013-0050.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"7","key":"109_CR12","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1210\/jc.2009-2546","volume":"95","author":"SA Rivkees","year":"2010","unstructured":"Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of Propylthiouracil and Methimazole in children. J Clin Endocrinol Metab. 2010;95(7):3260\u20137. https:\/\/doi.org\/10.1210\/jc.2009-2546.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"109_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0090-1229(83)90186-1","volume":"28","author":"AP Weetman","year":"1983","unstructured":"Weetman AP, McGregor AM, Hall R. Methimazole inhibits thyroid autoantibody production by an action on accessory cells. Clin Immunol Immunopathol. 1983;28(1):39\u201345. https:\/\/doi.org\/10.1016\/0090-1229(83)90186-1.","journal-title":"Clin Immunol Immunopathol"},{"issue":"2","key":"109_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000337976","volume":"1","author":"C Marcocci","year":"2012","unstructured":"Marcocci C, Leo M, Altea MA. Oxidative stress in graves\u2019 disease. Eur Thyroid J. 2012;1(2):80\u20137. https:\/\/doi.org\/10.1159\/000337976.","journal-title":"Eur Thyroid J"},{"issue":"20","key":"109_CR15","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. Selenium and the course of mild graves\u2019 orbitopathy. N Engl J Med. 2011;364(20):1920\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1012985.","journal-title":"N Engl J Med"},{"key":"109_CR16","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1136\/bmj.288.6416.518","volume":"288","author":"AP Weetman","year":"1984","unstructured":"Weetman AP, Holt ME, Campbell AK, et al. Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression. Br Med J (Clin Res Ed). 1984;288:518\u201320.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"2","key":"109_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1089\/thy.2012.0612","volume":"24","author":"H Ohye","year":"2014","unstructured":"Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, Watanabe N, et al. Antithyroid drug treatment for graves\u2019 disease in children: a long-term retrospective study at a single institution. Thyroid. 2014;24(2):200\u20137. https:\/\/doi.org\/10.1089\/thy.2012.0612.","journal-title":"Thyroid."},{"issue":"10","key":"109_CR18","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1210\/jcem.85.10.6922","volume":"85","author":"L Lazar","year":"2000","unstructured":"Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in Prepubertal children compared with pubertal and Postpubertal patients. J Clin Endocrinol Metab. 2000;85(10):3678\u201382. https:\/\/doi.org\/10.1210\/jcem.85.10.6922.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"109_CR19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/cen.13099","volume":"85","author":"S Rabon","year":"2016","unstructured":"Rabon S, Burton AM, White PC. Graves\u2019 disease in children: long-term outcomes of medical therapy. Clin Endocrinol. 2016;85(4):632\u20135. https:\/\/doi.org\/10.1111\/cen.13099.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"109_CR20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/thy.2016.0343","volume":"27","author":"V Sundaresh","year":"2017","unstructured":"Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative effectiveness of treatment choices for Graves\u2019 hyperthyroidism: a historical cohort study. Thyroid. 2017;27(4):497\u2013505. https:\/\/doi.org\/10.1089\/thy.2016.0343.","journal-title":"Thyroid."},{"issue":"6","key":"109_CR21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/cen.13133","volume":"85","author":"N Aggarwal","year":"2016","unstructured":"Aggarwal N, Tee SA, Saqib W, Fretwell T, Summerfield GP, Razvi S. Treatment of hyperthyroidism with antithyroid drugs corrects mild neutropenia in Graves\u2019 disease. Clin Endocrinol. 2016;85(6):949\u201353. https:\/\/doi.org\/10.1111\/cen.13133.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"109_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2265.2004.02135.x","volume":"61","author":"SH Pearce","year":"2004","unstructured":"Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol. 2004;61(5):589\u201394. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02135.x.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"109_CR23","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.4158\/EP11339.CR","volume":"18","author":"P Mutharasan","year":"2012","unstructured":"Mutharasan P, Oatis W, Kwaan H, Molitch M. Delayed anithyroid drug-induced agranulocytosis. Endocr Pract. 2012;18(4):e69\u201372. https:\/\/doi.org\/10.4158\/EP11339.CR.","journal-title":"Endocr Pract"},{"issue":"1","key":"109_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40268-017-0172-1","volume":"17","author":"N Vicente","year":"2017","unstructured":"Vicente N, Cardoso L, Barros L, Carrilho F. Antithyroid drug-induced agranulocytosis: state of the art on diagnosis and management. Drugs R D. 2017;17(1):91\u20136. https:\/\/doi.org\/10.1007\/s40268-017-0172-1.","journal-title":"Drugs R D"},{"issue":"6","key":"109_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2213-8587(16)00113-3","volume":"4","author":"P Hallberg","year":"2016","unstructured":"Hallberg P, Eriksson N, Ibanez L, et al. Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol. 2016;4(6):507\u201316. https:\/\/doi.org\/10.1016\/S2213-8587(16)00113-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"109_CR26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/cpt.733","volume":"102","author":"TS Plantinga","year":"2017","unstructured":"Plantinga TS, Arts P, Knarren GH, Mulder AH, Wakelkamp IM, Hermus AR, et al. Rare NOX3 variants confer susceptibility to agranulocytosis during Thyrostatic treatment of Graves\u2019 disease. Clin Pharmacol Ther. 2017;102(6):1017\u201324. https:\/\/doi.org\/10.1002\/cpt.733.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"109_CR27","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1210\/jc.2011-1601","volume":"96","author":"NR van Veenendaal","year":"2011","unstructured":"van Veenendaal NR, Rivkees SA. Treatment of pediatric Graves\u2019 disease is associated with excessive weight gain. J Clin Endocrinol Metab. 2011;96(10):3257\u201363. https:\/\/doi.org\/10.1210\/jc.2011-1601.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"109_CR28","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and Management of Hyperthyroidism and Other Causes of thyrotoxicosis. Thyroid. 2016;26(10):1343\u2013421. https:\/\/doi.org\/10.1089\/thy.2016.0229.","journal-title":"Thyroid."},{"key":"109_CR29","doi-asserted-by":"crossref","unstructured":"Abraham P, Avenell A, McGeoch SC, et al. Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst Rev. 2010;(1):Cd003420.","DOI":"10.1002\/14651858.CD003420.pub4"},{"issue":"6","key":"109_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/eje.1.02169","volume":"154","author":"S Razvi","year":"2006","unstructured":"Razvi S, Vaidya B, Perros P, Pearce SHS. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves\u2019 disease. Eur J Endocrinol. 2006;154(6):783\u20136. https:\/\/doi.org\/10.1530\/eje.1.02169.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"109_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/08035259950168405","volume":"88","author":"J Raza","year":"1999","unstructured":"Raza J, Hindmarsh PC, Brook CG. Thyrotoxicosis in children: thirty years\u2019 experience. Acta Paediatr. 1999;88(9):937\u201341. https:\/\/doi.org\/10.1080\/08035259950168405.","journal-title":"Acta Paediatr"},{"key":"109_CR32","volume-title":"How do paediatricians use and monitor antithyroid drugs in the UK?","author":"N Lawrence","year":"2019","unstructured":"Lawrence N, Cheetham T, Elder C. How do paediatricians use and monitor antithyroid drugs in the UK? Clin Endocrinol: A clinician survey; 2019."},{"issue":"5","key":"109_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40618-019-01144-0","volume":"43","author":"MC Vigone","year":"2020","unstructured":"Vigone MC, Peroni E, Di Frenna M, Mora S, Barera G, Weber G. \u201cBlock-and-replace\u201d treatment in Graves\u2019 disease: experience in a cohort of pediatric patients. J Endocrinol Investig. 2020;43(5):595\u2013600. https:\/\/doi.org\/10.1007\/s40618-019-01144-0.","journal-title":"J Endocrinol Investig"},{"issue":"4","key":"109_CR34","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/cen.12478","volume":"81","author":"B Vaidya","year":"2014","unstructured":"Vaidya B, Wright A, Shuttleworth J, Donohoe M, Warren R, Brooke A, et al. Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves\u2019 disease: a retrospective observational study. Clin Endocrinol. 2014;81(4):610\u20133. https:\/\/doi.org\/10.1111\/cen.12478.","journal-title":"Clin Endocrinol"},{"issue":"6","key":"109_CR35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1530\/EJE-20-0617","volume":"183","author":"CL Wood","year":"2020","unstructured":"Wood CL, Cole M, Donaldson M, Dunger DB, Wood R, Morrison N, et al. Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis. Eur J Endocrinol. 2020;183(6):637\u201345. https:\/\/doi.org\/10.1530\/EJE-20-0617.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"109_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1210\/jc.2011-1944","volume":"97","author":"J Leger","year":"2012","unstructured":"Leger J, Gelwane G, Kaguelidou F, et al. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves\u2019 disease: national long-term cohort study. J Clin Endocrinol Metab. 2012;97(1):110\u20139. https:\/\/doi.org\/10.1210\/jc.2011-1944.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"109_CR37","doi-asserted-by":"publisher","first-page":"e20183034","DOI":"10.1542\/peds.2018-3034","volume":"143","author":"F Azizi","year":"2019","unstructured":"Azizi F, Takyar M, Madreseh E, Amouzegar A. Long-term Methimazole therapy in juvenile Graves\u2019 disease: a randomized trial. Pediatrics. 2019;143(5):e20183034. https:\/\/doi.org\/10.1542\/peds.2018-3034.","journal-title":"Pediatrics."},{"key":"109_CR38","doi-asserted-by":"publisher","unstructured":"van Lieshout JM, Mooij CF, van Trotsenburg ASP, Zwaveling-Soonawala N. Methimazole-Induced Remission Rates in Pediatric Graves\u2019 Disease: a Systematic Review. Eur J Endocrinol. 2021:EJE-21-0077.R1. https:\/\/doi.org\/10.1530\/EJE-21-0077.","DOI":"10.1530\/EJE-21-0077"},{"issue":"5","key":"109_CR39","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1172\/JCI109601","volume":"64","author":"LC Wood","year":"1979","unstructured":"Wood LC, Ingbar SH. Hypo-Thyroidism as a late sequela in patients with graves-disease treated with anti-thyroid agents. J Clin Invest. 1979;64(5):1429\u201336. https:\/\/doi.org\/10.1172\/JCI109601.","journal-title":"J Clin Invest"},{"issue":"6","key":"109_CR40","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1210\/endrev\/bnaa022","volume":"41","author":"LC Lane","year":"2020","unstructured":"Lane LC, Cheetham TD, Perros P, Pearce SHS. New therapeutic horizons for Graves\u2019 hyperthyroidism. Endocr Rev. 2020;41(6):873\u201384. https:\/\/doi.org\/10.1210\/endrev\/bnaa022.","journal-title":"Endocr Rev"},{"issue":"1","key":"109_CR41","doi-asserted-by":"publisher","first-page":"e024705","DOI":"10.1136\/bmjopen-2018-024705","volume":"9","author":"M Cole","year":"2019","unstructured":"Cole M, Hynes AM, Howel D, Hall L, Abinun M, Allahabadia A, et al. Adjuvant rituximab, a potential treatment for the young patient with Graves\u2019 hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial. BMJ Open. 2019;9(1):e024705. https:\/\/doi.org\/10.1136\/bmjopen-2018-024705.","journal-title":"BMJ Open"},{"issue":"7","key":"109_CR42","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1089\/thy.2019.0036","volume":"29","author":"SHS Pearce","year":"2019","unstructured":"Pearce SHS, Dayan C, Wraith DC, Barrell K, Olive N, Jansson L, et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves\u2019 hyperthyroidism: a phase I study. Thyroid. 2019;29(7):1003\u201311. https:\/\/doi.org\/10.1089\/thy.2019.0036.","journal-title":"Thyroid."},{"issue":"11","key":"109_CR43","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1210\/jc.2013-4466","volume":"99","author":"K Okamura","year":"2014","unstructured":"Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, Kitazono T. Remission after potassium iodide therapy in patients with Graves\u2019 hyperthyroidism exhibiting thionamide-associated side effects. J Clin Endocrinol Metab. 2014;99(11):3995\u20134002. https:\/\/doi.org\/10.1210\/jc.2013-4466.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"109_CR44","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1210\/jc.2008-0842","volume":"93","author":"F Kaguelidou","year":"2008","unstructured":"Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, L\u00e9ger J, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008;93(10):3817\u201326. https:\/\/doi.org\/10.1210\/jc.2008-0842.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"109_CR45","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/cen.14359","volume":"94","author":"LC Lane","year":"2021","unstructured":"Lane LC, Rankin J, Cheetham T. A survey of the young person\u2019s experience of Graves\u2019 disease and its management. Clin Endocrinol. 2021;94(2):330\u201340. https:\/\/doi.org\/10.1111\/cen.14359.","journal-title":"Clin Endocrinol"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-021-00109-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13044-021-00109-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-021-00109-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T02:21:55Z","timestamp":1672885315000},"score":1,"resource":{"primary":{"URL":"https:\/\/thyroidresearchjournal.biomedcentral.com\/articles\/10.1186\/s13044-021-00109-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["109"],"URL":"https:\/\/doi.org\/10.1186\/s13044-021-00109-x","relation":{},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"28 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No formal ethics approval was required when writing this article and the patients whose non-identifiable data was used to generate Figs.\u00a0andagreed to their presentation \/ inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}